PHARMACOECONOMIC MODELS IN RHEUMATOLOGY

Abstract

Pharmacoeconomic models of chronic diseases explore the development of the disease, patients' pathways through it and calculate the cost-eff ectiveness of the therapy with diff erent medicines. The goal of the current study is to identify the pharmacoeconomic models used in rheumatology, their historical development and utilization. Systematic search in PubMed was performed with key words "pharmacoeconomic, models, rheumatology, and cost-eff ectiveness". On total 58 manuscripts were identifi ed, describing mainly the rheumatoid arthritis development. The fi rst one in line is the ACCES model of rheumatoid arthritis which have been validated in Sweden, Norway, etc. This is one of the fi rst Markov models in rheumatology. Biological medicines are in the primary area of interest for modelling their therapeutic results. During the latest year scientists are working for the development of the web based platform to forecast the biological therapy (model PREDIRA). In alliance with other therapeutic areas with the development of artifi cial intelligence the pharmacoeconomic models is expected to increase, especially those built with data from real world clinical practice.